Genmab A/S (OTCMKTS:GNMSF – Get Free Report) gapped up before the market opened on Tuesday. The stock had previously closed at $367.00, but opened at $388.00. Genmab A/S shares last traded at $388.00, with a volume of 402 shares traded.
Genmab A/S Trading Up 3.2%
The firm has a market cap of $24.01 billion, a price-to-earnings ratio of 30.59 and a beta of 0.75. The business has a fifty day moving average of $343.65 and a two-hundred day moving average of $295.42. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46.
Genmab A/S Company Profile
Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.
Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.
Further Reading
- Five stocks we like better than Genmab A/S
- Powering Up: Applied Digital Execs Buy $6.7M in Stock
- Chip Stocks Are Sliding—Why Is Smart Money Buying?
- Adults Are Fueling a Toy Boom—These 4 Stocks Could Cash In
- Could Quantinuum’s Breakthrough Make Its Sell-Off a Bargain?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
